| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.19 | 2e-06 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-06 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.24 | 7e-06 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.24 | 9e-06 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.16 | 3e-05 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-05 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.18 | 7e-05 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.13 | 9e-05 |